TV Presenter & Finance EditorTV presenter and finance editor at Grafa, with a Master’s in Commerce from UWA and diverse industry experience in finance, insurance, and media.
Swan Bitcoin’s lawsuit against Proton Management and several former employees was dismissed by a California federal judge on June 1 after Swan conceded in related UK proceedings that it never owned the mining assets and trade secrets underpinning its claims.
Elliott Investment Management takes a $1b stake in Northern Star Resources (ASX:NST), demanding a review and external CEO.
Credo Technology Group Holding (NASDAQ:CRDO) reported its financial and operating results for the fourth quarter and full fiscal year 2026 ended May 2, 2026, delivering triple-digit top-line expansion fueled by accelerated global demand for high-speed, energy-efficient data connectivity infrastructure.
Worldcoin gained as much as 8% after World Network announced a partnership with Thirty Seconds to Mars that uses World ID technology to provide human-only access to selected concert ticket sales.
IDEAYA Biosciences (NASDAQ:IDYA) and Servier reported complete data Monday from the primary analysis of their registrational Phase 2/3 OptimUM-02 clinical trial.
Crypto trading firm Wintermute has expanded into prediction markets, aiming to provide liquidity across event-based contracts as the sector experiences rapid growth.
Greenwich LifeSciences (NASDAQ:GLSI) reported new open-label immune response data from its ongoing Phase III FLAMINGO-01 clinical trial evaluating its lead immunotherapy candidate, GLSI-100, in patients with HER2-positive breast cancer.
A $1.26 billion block trade in BlackRock’s iShares Bitcoin Trust last week was likely a large investor exiting a concentrated Bitcoin position rather than unwinding a market-neutral strategy, according to NYDIG.
AstraZeneca (NASDAQ:AZN) unveiled positive data from its late-stage EMERALD-3 clinical trial on Monday, demonstrating that adding its dual-immunotherapy regimen to standard localized therapy significantly slows disease progression in patients battling early-stage, unresectable liver cancer.
Citius Oncology (NASDAQ:CTOR) showcased positive early-stage clinical trial results, demonstrating the potential of its targeted immune therapy LYMPHIR to enhance the efficacy of checkpoint inhibitors in treating recurrent or refractory gynecologic cancers.
